Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer

J Thorac Oncol. 2017 Jul;12(7):e85-e88. doi: 10.1016/j.jtho.2017.02.020. Epub 2017 Mar 6.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acrylamides
  • Adult
  • Aniline Compounds
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Crizotinib / pharmacology
  • Crizotinib / therapeutic use*
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*

Substances

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • Piperazines
  • osimertinib
  • Crizotinib
  • EGFR protein, human
  • ErbB Receptors